Potters L
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Oncology (Williston Park). 2000 Jul;14(7):981-91; discussion 991-2, 997-9.
Current techniques for permanent prostate brachytherapy are associated with excellent biochemical control in patients with localized prostate cancer. Data now available confirm 5- to 10-year results with this treatment modality that are comparable to those with external-beam irradiation or radical prostatectomy. Nonetheless, treatment protocols and techniques for prostate brachytherapy vary from center to center. Controversy exists regarding the selection of patients for brachytherapy alone or in combination with external-beam irradiation. The role of neoadjuvant androgen deprivation also remains undefined in patients with localized prostate cancer. Matched-pair analysis studies performed at Memorial Sloan-Kettering Cancer Center have examined the role of isotope selection, the addition of external-beam irradiation, and the use of neoadjuvant androgen deprivation. These studies provide insights into the use of permanent brachytherapy in patients with localized prostate cancer. In addition, postimplant dosimetry needs to be a requirement for centers performing seed implants. Data now appear to support specific computed tomography-based criteria to evaluate implant quality and delivered dose to the prostate. Unfortunately, prostate edema and poor imaging techniques limit the evaluation of implant dosimetry. Treatment planning techniques that utilize new imaging modalities, coupled with computerized treatment planning, may help improve the implant procedure and dosimetry.
目前用于永久性前列腺近距离放射治疗的技术,在局限性前列腺癌患者中可实现出色的生化控制。现有数据证实了这种治疗方式5至10年的治疗效果,与外照射放疗或根治性前列腺切除术相当。尽管如此,前列腺近距离放射治疗的治疗方案和技术在不同中心之间存在差异。对于仅接受近距离放射治疗或联合外照射放疗的患者选择,仍存在争议。新辅助雄激素剥夺在局限性前列腺癌患者中的作用也尚不明确。纪念斯隆凯特琳癌症中心进行的配对分析研究,探讨了同位素选择、添加外照射放疗以及使用新辅助雄激素剥夺的作用。这些研究为局限性前列腺癌患者使用永久性近距离放射治疗提供了见解。此外,对于进行粒子植入的中心,植入后剂量测定应成为一项要求。目前的数据似乎支持基于特定计算机断层扫描的标准,以评估植入质量和前列腺所接受的剂量。不幸的是,前列腺水肿和欠佳的成像技术限制了对植入剂量测定的评估。利用新成像模式并结合计算机化治疗计划的治疗计划技术,可能有助于改进植入程序和剂量测定。